Case number# PHHY2015BR056877 is an initial spontaneous report from a physician received via pharmaceutical 
company (Biogen) on 05 May 2015.
This report refers to a 25-year-old female patient. Medical history was not reported. No concomitant medication was
reported. The patient was on prior Tysabri treatment as the case was received from Biogen. 
The patient received Gilenya (fingolimod) capsule, for an unknown indication, start date and dose (unknown route).
On an unknown date, the patient developed PML suspect (progressive multifocal leukoencephalopathy). Action 
taken with Gilenya was unknown.
The outcome of the event was not reported. The event "PML suspect" was assessed as serious by the physician. 
The causality of the event was not reported.
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 440 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
This case was processed with very limited information received from Biogen and Novartis has not received any 
reporter contact details and consent to contact him directly. Novartis will do an active follow-up on the case after 
receiving reporter contact details and consent from Biogen.